Blood Cancer JournalHellou et al.Original Research
Impact of residual clonal plasma cell proliferation rate after autologous stem cell transplant on outcomes in multiple myeloma
Multiple myeloma (MM) is characterized by substantial biological heterogeneity, with outcomes influenced by baseline disease characteristics and depth of response to therapy [ 1 ]. Measurable residual disease (MRD) has emerged as a powerful post-treatment prognostic marker; however, assessment of residual disease burden does not directly characterize the proliferative behavior of the remaining clonal plasma cells [ 2 ]. Plasma cell proliferation, quantified by the proportion of clonal plasma cells in S-phase, provides complementary information regarding disease biology. We recently demonstrated that elevated S-phase percentage (S-phase %) identifies patients with inferior outcomes both at diagnosis [ 3 ] and at the time of autologous stem cell transplantation (ASCT) [ 4 ]. Post-transplant plasma cell proliferation has also demonstrated prognostic value among patients failing to achieve complete response after ASCT [ 5 ]. However, the prognostic significance of post-ASCT S-phase in a broader contemporary cohort, and particularly the impact of dynamic changes in proliferative activity from the time of transplantation to the post-transplant period, remain incompletely characterized. We therefore evaluated the prognostic significance of post-ASCT clonal plasma cell S-phase % and its dynamic change following ASCT in patients with MM. We retrospectively identified patients with MM who underwent ASCT within one year of diagnosis at Mayo Clinic, Rochester, between January 1, 2013 and August 31, 2024. Of 1136 eligible patients, 81 lacked an appropriate post-ASCT marrow assessment or experienced progression/death before the landmark, leaving 1055 patients for analysis (Supplementary Fig. 1 ). Post-ASCT bone marrow assessment was performed at day +60 (days 45–75) and/or day +100 (days 76–130); when both were available, the earlier assessment was used. Clonal plasma cell S-phase was assessed using the Mayo Clinic plasma cell proliferative rate by flow cytometry (PCPRO) assay. Multiparameter flow cytometry incorporating CD19, CD38, CD45, CD138, cytoplasmic kappa/lambda light chains, and DAPI was used to identify clonal plasma cells and assess DNA content. Clonal plasma cells were identified based on aberrant immunophenotype and light-chain restriction, and the proportion of clonal plasma cells in S-phase was determined from DNA content analysis. S-phase was quantifiable when ≥300 abnormal plasma cells were available. Approximately 500,000 total events were routinely acquired per sample; thus, the 300-cell requirement corresponds to approximately 6 × 10⁻⁴ of acquired events, allowing S-phase determination even in samples with relatively low residual plasma-cell burden. This threshold represents an analytical adequacy requirement for reliable cell-cycle assessment and should not be interpreted as an MRD sensitivity threshold or as corresponding to a specific bone marrow plasma-cell percentage. S-phase was categorized using the previously established cutoff of <2% versus ≥2% [ 3 , 4 ]. Samples with absent or insufficient clonal plasma cells for S-phase determination were classified as non-assessable (N/A). Landmark progression-free survival (PFS) and overall survival (OS) were calculated from the post-ASCT assessment. In patients with paired S-phase assessments at ASCT and post-ASCT, dynamic changes in proliferative activity were categorized using the 2% cutoff at both time points as low-low, high-low, low-high, or high-high. Categorical and continuous variables were compared using chi-square/Fisher’s exact and Wilcoxon rank-sum tests, respectively. Survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Multivariable Cox regression was used to evaluate the independent prognostic significance of S-phase. Among the 1,055 patients with an evaluable post-ASCT bone marrow assessment, S-phase was quantifiable in 172 patients: 122 (11.6%) had S-phase <2% and 50 (4.7%) had S-phase ≥2%. In the remaining 883 patients (83.7%), S-phase was N/A because of absent or insufficient clonal plasma cells, generally reflecting a deep hematologic response following ASCT. Baseline characteristics of the three groups are summarized in (Supplementary Table 1 ). Among patients with quantifiable S-phase, median age and sex distribution were similar between the S-phase <2% and ≥2% groups. Patients with S-phase ≥2% were more likely to have ISS stage III disease (35% vs. 17%, p = 0.03), while high-risk cytogenetics, induction therapy prior to ASCT and post-ASCT hematologic response did not differ significantly between groups. Patients with S-phase ≥2% were also numerically more likely to receive no maintenance therapy after ASCT than those with S-phase <2% (34% vs. 20%) although this difference did not reach statistical significance ( p = 0.06). Outcomes differed significantly across the three post-ASCT S-phase groups (Fig. 1A ). Median PFS was 95 months in the N/A group, 37 months in the S-phase <2% group, and 11 months in the S-phase ≥2% group ( p < 0.0001). Median OS was not reached (NR) in both the N/A and S-phase <2% groups and was 53 months in the S-phase ≥2% group ( p < 0.0001) (Fig. 1B ). We next evaluated dynamic changes in plasma cell proliferation among patients with quantifiable S-phase both at ASCT and post-ASCT ( n = 160). Patients were categorized according to S-phase <2% or ≥2% at each time point. Median PFS was 37 months for low-low ( n = 106), 22 months for high-low ( n = 10), 17 months for low-high ( n = 24), and 7 months for high-high ( n = 20) patients ( p < 0.001) (Fig. 2A ). Median OS was NR for the low-low and high-low groups, 83 months for the low-high group, and 25 months for the high-high group ( p < 0.001) (Fig. 2B ). These findings demonstrate that persistently elevated S-phase was associated with the poorest outcomes, while the emergence of elevated S-phase after ASCT was also associated with inferior outcomes despite a low S-phase at transplantation. Among 172 patients with quantifiable S-phase, S-phase ≥2% remained independently associated with inferior PFS (HR 1.9, 95% CI 1.1–3.1; p = 0.01) after adjustment for age, ISS stage, high-risk FISH, maintenance therapy, and post-ASCT response. For OS, given the smaller number of events, the multivariable model included S-phase, ISS stage, and high-risk FISH; S-phase ≥2% remained independently associated with inferior OS (HR 3.3, 95% CI 1.5–7.0; p = 0.002) (Supplementary Table 2 ). Given the numerical difference in maintenance use between the S-phase groups, we performed a sensitivity analysis restricted to patients who received post-ASCT maintenance (n = 130). Median PFS remained significantly shorter in patients with S-phase ≥2% compared with S-phase <2% (10.0 vs. 41.7 months; p < 0.001) (Supplementary Fig. 2 ). Median transplant year was 2019 in both S-phase groups ( p = 0.354), indicating no significant difference in treatment era. Given the distinct response kinetics of t(11;14) myeloma, in which residual disease may persist despite favorable outcomes, we explored whether post-ASCT S-phase could further discriminate prognosis within this subgroup. Among patients with t(11;14) and quantifiable post-ASCT S-phase ( n = 63), median PFS was 33.7 months with S-phase <2% compared with 8.7 months with S-phase ≥2% (HR 3.61, 95% CI 1.90–6.86; p < 0.001) (Supplementary Fig. 3 ). Fig. 1: Survival outcomes according to post-ASCT clonal plasma cell S-phase %, stratified as S-phase <2%, S-phase ≥2%, or non-assessable (N/A). Full size image A Progression-free survival (PFS). B Overall survival (OS). Fig. 2: Survival outcomes according to dynamic changes in clonal plasma cell S-phase from ASCT to post-ASCT assessment, categorized as low→low, high→low, low→high, or high→high using a 2% cutoff. Full size image A Progression-free survival (PFS). B Overall survival (OS).
